DOI:

The latest news from the European Association for Percutaneous Cardiovascular Interventions (EAPCI)

William Wijns*, President EAPCI

As a reader of EuroIntervention Journal, percutaneous cardiovascular intervention must be your primary interest. If so, please take a few moments to read the following update news from your association, the European Association for Percutaneous Cardiovascular Interventions, known as the EAPCI.

EAPCI was formally launched at the World Congress 2006 in Barcelona as a registered branch of the European Society of cardiology. We share the ESC mission, albeit focused on our field of activity:

“To reduce the burden of cardiovascular disease in Europe

through Percutaneous Cardiovascular Interventions”

and the KEYWORDS that govern our action are:

Synergy

Focus

and Credibility.

Even though so recently born, EAPCI is already able to offer you important assets, represented by the heritage of its proud parents (EuroPCR and Working Group 10):

– EuroPCR Course, to take place this year for the first time in Barcelona, on the 22nd-25th May 2007,

– EuroPCRonline.com, featuring outstanding educational content, and the EAPCI website accessible on ESCardio.org,

– Euro Heart Survey and Registry,

– A comprehensive Education-Training-Accreditation programme,

– and not to forget, EuroIntervention Journal itself.

For EAPCI, strengths and opportunities are many. The coalition formed by the EuroPCR team – representing nearly two decades of commitment to education and teaching – along with the European Society of Cardiology – “the” representative cardiovascular medical scientific society in Europe and beyond – is a unique model. The blend of both cultures will materialise strong synergies as we consolidate our current assets and explore new activities.

At a moment where our field is experiencing another wave of expansion, leadership will be needed more than ever. To this end, EAPCI will rely entirely on a close collaboration with the national Working Groups, Societies or other bodies representing interventional communities throughout Europe, as the building blocks of our action. EAPCI can only be successful when governed by a “bottom up” relationship with its constituency.

At the beginning of the three-year term of this Board, many new initiatives are being considered, but at this present time please consider what we already have up and running right now. EAPCI leadership is structured in 8 Committees, each having a well defined mission that will be further delineated on our website and future newsletters: Communication, Euro Heart Survey, Scientific Initiatives, National Membership, Education, Fellowship, Accreditation and Clinical Initiatives. Through your national representatives, you will be asked to join and engage in these various committees, making EAPCI an essential component of your professional life in the years to come.

EAPCI Board 2006-2009.

Rows from left to right and from bottom to top,

– Marc van Sambeek, Keren Deront (EAPCI Office at ESC), Carlo Di Mario (President-Elect),

– Antoine Lafont, Sigmund Silber, Darius Dudek (Secretary),

– Martyn Thomas, Andreas Baumbach, Jean Marco, Jan-Erik Nordrehaug,

– Alberto Cremonesi, Franz Eberli, Horst Sievert (Treasurer), Franz Weidinger, William Wijns (President),

– Bernard Chevalier, Ran Kornowski, Jean Fajadet, Alec Vahanian, Alan Howard (CEO ESC).

Missing on the picture are Sally Vincent (EuroPCR office), Marc Doncieux (CEO Europa) and Patrick Serruys.

Volume 2 Number 4
Feb 20, 2007
Volume 2 Number 4
View full issue


Key metrics

Suggested by Cory

Trial Design

10.4244/EIJ-D-25-00486 Sep 30, 2025
Mechanical circulatory support in high-risk elective PCI: rationale and design of the PROTECT IV trial
Mangner N et al
free

Editorial

10.4244/EIJ-E-25-00022 Sep 15, 2025
An ongoing quest to discern the optimal antithrombotic therapy after TAVI
Hayashida K and Iwata J
free

Research Correspondence

10.4244/EIJ-D-25-00255 Sep 15, 2025
Redo-TAVI with the ACURATE platform for failure of short-frame transcatheter heart valves
Tarantini G et al

Editorial

10.4244/EIJ-E-25-00038 Sep 15, 2025
Evolving cutoff values for optimising left main stenting with intravascular imaging
de la Torre Hernandez J
free

Original Research

10.4244/EIJ-D-24-01066 Sep 15, 2025
VARC-HBR criteria validation in TAVI patients on oral anticoagulation
Overduin D et al

Translational research

10.4244/EIJ-D-24-01000 Sep 15, 2025
DurAVR – a novel biomimetic balloon-expandable transcatheter valve for TAVI, valve-in-valve TAVI and redo-TAVI
Meier D et al
open access

Flashlight

10.4244/EIJ-D-25-00121 Sep 15, 2025
Calcium mapping by 3DStent technology
Amabile N and Benamer H

State-of-the-Art

10.4244/EIJ-D-24-00992 Sep 15, 2025
Antithrombotic therapy in complex percutaneous coronary intervention
Castiello D et al
free
Trending articles
96.55

State-of-the-Art

10.4244/EIJ-D-24-00066 Apr 21, 2025
Management of complications after valvular interventions
Bansal A et al
free
67.15

State-of-the-Art

10.4244/EIJ-D-24-00992 Sep 15, 2025
Antithrombotic therapy in complex percutaneous coronary intervention
Castiello D et al
free
56.1

Original Research

10.4244/EIJ-D-25-00331 May 21, 2025
One-month dual antiplatelet therapy followed by prasugrel monotherapy at a reduced dose: the 4D-ACS randomised trial
Jang Y et al
open access
56.1

Original Research

10.4244/EIJ-D-25-00331 Jul 21, 2025
One-month dual antiplatelet therapy followed by prasugrel monotherapy at a reduced dose: the 4D-ACS randomised trial
Jang Y et al
open access
35.45

State-of-the-Art

10.4244/EIJ-D-23-00448 Jan 15, 2024
Coronary spasm and vasomotor dysfunction as a cause of MINOCA
Yaker ZS et al
free
X

PCR
Impact factor: 9.5
2024 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2025)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2025 Europa Group - All rights reserved